Table 1.

List of monkeys subjected to permanent primary motor cortex lesion and included in the present study with identification code

	Mk-CE	Mk-JU	Mk-GE	Mk-RO	Mk-BI	Mk-VA	Mk-SL	Mk-MO	Mk-AV	Mk-JO	Mk-JA
Treatment	None	None	None	None	None	Anti-Nogo-A antibody	Anti-Nogo-A antibody	Anti-Nogo-A antibody	Sham-cell therapy	Cell therapy	Cell therapy
Age at time of lesion (rounded 0.5 year)	4.5	5	5	4	5	5.5	5.5	5.5	3.5	3.5	4
Weight at time of lesion	3.8	3.6	2.8	3.2	5	4.9	4.6	5.6	4.3	3.4	4.3
Volume of ibotenic acid injected (μl)	40	40	13	18	29.7	15.5	18	20	15	15	38a
No. of ICMS sites injected with ibotenic acid	21	21	13	12	29	11	12	20	10	10	38
Total volume of lesion (mm³), gray matter (motor cortex + post-central gyrus)	112.8	63.01	48.7	14	20.13	20	78.2	41.8	33.2	33.6	22.2
Volume of lesion in post-central gyrus (mm³)	10.1	0	7.6	0	0	5.8	1.8	0	0	3.8	2.5
Lesion spread subcortically to the white matter (mm³)	86.5	28.9	0	0	0	0	130.6	0	69.8	23.6	38.4

Mk-LA (involved only in the transient inactivation of M1 with infusion of muscimol) was 5 years old and weighted 2.6 kg. A total volume of 15 μl of muscimol was infused in M1, at 10 sites, previously identified based on ICMS (see text)

^aIn Mk-JA, nearly the same amount of ibotenic acid was injected as in the first two monkeys (Mk-CE and Mk-JU). However, in contrast to the other two monkeys, Mk-JA suffered several epileptic attacks immediately after the lesion. The monkey Mk-JA was treated with an anti-epileptic drug (Luminal), preventing other episodes. The anti-epileptic drug is known to counteract the excitotoxic effect of ibotenic acid, yielding a smaller volume of lesion as compared to the other two monkeys which received a comparable volume of ibotenic acid